The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
Arvinas’s vepdegestrant (VEPPANU) marks a regulatory milestone as the first proteolysis-targeting chimera to win FDA approval, offering a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve …
One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
SUMMIT trial shows bezuclastinib reduces symptom burden and mast cell markers significantly in non-advanced systemic mastocytosis
Already a subscriber? Log in